Trial · NCT02986178

Lerapolturev in Recurrent Malignant Glioma

NCT02986178, Phase 2, Completed, Istari Oncology, Inc.; results first posted 2025-07-11

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. Lerapolturev in Recurrent Malignant Glioma. Trials, record NCT02986178. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02986178

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: Lerapolturev in Recurrent Malignant Glioma
NCT number: NCT02986178
Status: Completed
Phases: Phase 2
Enrollment: 121 participants, actual
Lead sponsor: Istari Oncology, Inc.
Conditions: Malignant Glioma
Interventions: lerapolturev, Lomustine
First posted: 2016-12-08
Last updated: 2025-07-11
Results first posted: 2025-07-11

Source ClinicalTrials.gov

Registered outcomes6

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	Number of Participants With Objective Radiographic Response	up to 5 years	Assess objective anti-tumor response based on iRANO criteria.
Primary	Duration of Objective Radiographic Response	up to 5 years	Assess time of confirmed response to confirmed disease progression or death
Secondary	Median Overall Survival	up to 5 years	Overall Survival (months), calculated using the Kaplan-Meier method
Secondary	Landmark Survival	at 24 and 36 months post-lerapolturev infusion	Overall survival (months) at 24 and 36 months, calculated using the Kaplan-Meier method
Secondary	Disease Control Rate	up to 5 years	the percentage of participants achieving complete response, partial response, or stable disease
Secondary	Safety of Lerapolturev	up to 52 weeks	Number of participants experiencing Grade 3, 4 or 5 adverse events considered possibly, probably, or definitely related to protocol treatment

Source ClinicalTrials.gov

Outcomes6

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Population	Units	Measured as
PRIMARY	Number of Participants With Objective Radiographic Response	up to 5 years		Participants	COUNT_OF_PARTICIPANTS
PRIMARY	Duration of Objective Radiographic Response	up to 5 years		months	MEDIAN
SECONDARY	Median Overall Survival	up to 5 years		months	MEDIAN
SECONDARY	Landmark Survival	at 24 and 36 months post-lerapolturev infusion		proportion probability	NUMBER
SECONDARY	Disease Control Rate	up to 5 years		percentage of participants	NUMBER
SECONDARY	Safety of Lerapolturev	up to 52 weeks	The safety set includes all participants who had an infusion catheter placed.	Participants	COUNT_OF_PARTICIPANTS

Source ClinicalTrials.gov

Results by group14

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Category	Value	Spread	Units
Number of Participants With Objective Radiographic Response	Lerapolturev		5		Participants
Number of Participants With Objective Radiographic Response	Lerapolturev + Lomustine		2		Participants
Duration of Objective Radiographic Response	Lerapolturev		NA	95% Confidence Interval NA to NA	months
Duration of Objective Radiographic Response	Lerapolturev + Lomustine		NA	95% Confidence Interval NA to NA	months
Median Overall Survival	Lerapolturev		7.0	95% Confidence Interval 5.8 to 9.1	months
Median Overall Survival	Lerapolturev + Lomustine		7.1	95% Confidence Interval 4.0 to 8.1	months
Landmark Survival	Lerapolturev	Probability of being alive at 24 months	0.12	95% Confidence Interval 0.06 to 0.21	proportion probability
Landmark Survival	Lerapolturev + Lomustine	Probability of being alive at 24 months	0.19	95% Confidence Interval 0.07 to 0.35	proportion probability
Landmark Survival	Lerapolturev	Probability of being alive at 36 months	0.07	95% Confidence Interval 0.02 to 0.15	proportion probability
Landmark Survival	Lerapolturev + Lomustine	Probability of being alive at 36 months	0.11	95% Confidence Interval 0.03 to 0.26	proportion probability

1 to 10 of 14Source ClinicalTrials.gov

See all 14 results by group

Participant flow9

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
Overall Study	STARTED	Lerapolturev	93
Overall Study	STARTED	Lerapolturev + Lomustine	27
Overall Study	STARTED	Not Treated	1
Overall Study	COMPLETED	Lerapolturev	93
Overall Study	COMPLETED	Lerapolturev + Lomustine	27
Overall Study	COMPLETED	Not Treated	0
Overall Study	NOT COMPLETED	Lerapolturev	0
Overall Study	NOT COMPLETED	Lerapolturev + Lomustine	0
Overall Study	NOT COMPLETED	Not Treated	1

Source ClinicalTrials.gov

Adverse events348

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

Type	Event	Organ system	Group	Affected	At risk
other	headache	Nervous system disorders	Lerapolturev	63	94
other	headache	Nervous system disorders	Lerapolturev + Lomustine	22	26
other	headache	Nervous system disorders	Overall	85	121
other	hemiparesis	Nervous system disorders	Lerapolturev	63	94
other	hemiparesis	Nervous system disorders	Lerapolturev + Lomustine	22	26
other	hemiparesis	Nervous system disorders	Overall	85	121
other	seizure	Nervous system disorders	Lerapolturev	40	94
other	seizure	Nervous system disorders	Lerapolturev + Lomustine	17	26
other	seizure	Nervous system disorders	Overall	57	121
other	aphasia	Nervous system disorders	Lerapolturev	35	94

1 to 10 of 348Source ClinicalTrials.gov

See all 348 adverse events

Adverse event totals9

The totals the trial posted for each group.

Total	Group	Affected	At risk
Total, all-cause mortality	Lerapolturev	8	94
Total, all-cause mortality	Lerapolturev + Lomustine	4	26
Total, all-cause mortality	Overall	12	121
Total, other adverse events	Lerapolturev	94	94
Total, other adverse events	Lerapolturev + Lomustine	26	26
Total, other adverse events	Overall	121	121
Total, serious adverse events	Lerapolturev	37	94
Total, serious adverse events	Lerapolturev + Lomustine	12	26
Total, serious adverse events	Overall	50	121

Source ClinicalTrials.gov

Papers1

The papers the trial lists on ClinicalTrials.gov.

PMID	Listed as
37072349	DERIVED

Source PubMed

Grants0

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

None in this release.

Trial comparisons2

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

Comparison	Source
Lerapolturev vs Lerapolturev + Lomustine: Number of Participants With Objective Radiographic Response	Trial comparisons
Lerapolturev vs Lerapolturev + Lomustine: Safety of Lerapolturev	Trial comparisons

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT02986178

GET https://conductscience.org/api/trials/v1/NCT02986178/events?page=2

API reference For AI assistants